Home・Lista de Ações・Danaher Corp

Danaher Corp

Fechado

SetorSaúde

194.61 -1.46

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

192.43

Máximo

199.67

Indicadores-chave
By Trading Economics
Rendimento	-159M 870M
Vendas	314M 6.3B
P/E Médio do Setor	35.027 64.641
EPS	1.94
Rendimento de Dividendos	0.75
Margem de lucro	13.887
Funcionários	58,000
EBITDA	-364M 1.1B

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+11.28% upside

Dividendos
By Acuity
Rendimento de Dividendos Médio do Setor	0.75% 2.31%
Próximos Ganhos	20 de out. de 2026
Próxima data de dividendos	30 de out. de 2026
Próxima data de ex-dividendo	25 de set. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-4.2B 138B
Abertura anterior	196.07
Fecho anterior	194.61

Sentimento de Notícias

By Acuity

50%

151 / 340 Ranking em Healthcare

Danaher Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 22:51 UTC

News

Danaher Corp appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026. Shares are trading higher in after-market hours.

31 de jul. de 2026, 23:01 UTC

Danaher Corp shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market weakness.

30 de jul. de 2026, 18:01 UTC

Danaher Corp. shares are lower today, fluctuating within their one-month range amid volatility influenced by the Federal Reserve's interest rate decisions.

29 de jul. de 2026, 23:01 UTC

Danaher Corp shares are higher in after-market trading, reflecting a slight increase since Wednesday's close. The stock reached a recent high shortly after 5:10 PM ET.

28 de jul. de 2026, 23:01 UTC

Danaher Corp shares declined in after-hours trading amid broader market losses linked to concerns over artificial intelligence spending and competition from Chinese chipmakers.

27 de jul. de 2026, 23:16 UTC

Danaher Corp shares are lower in after-market trading, declining slightly since Monday's close. No specific company news has been identified to explain the movement.

24 de jul. de 2026, 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

23 de jul. de 2026, 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

22 de jul. de 2026, 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

21 de jul. de 2026, 19:41 UTC

News

Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

20 de jul. de 2026, 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Comparação entre Pares

Variação de preço

Danaher Corp Previsão

Preço-alvo

By TipRanks

11.28% parte superior

Previsão para 12 meses

Média 219.78 USD 11.28%

Máximo 240 USD

Mínimo 195 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Danaher Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

Comprar

Manter

Vender

Com base em 20 analistas que deram avaliações de ações para Danaher Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

151 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.